8-K ·Filed Apr 27, 2026

ABT

ABBOTT LABORATORIES
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago SEC0001104659-26-049434
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This is a routine administrative filing with no material new information. Monitor subsequent filings for actual equity grant details or shareholder vote outcomes, but no immediate trading action is warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
ABT ▲ +7.38% at T+60d
NEUTRAL call ✓ call won +7.38% · α vs SPY +3.66% · entry $93.83 → $100.75
Entry anchored
Apr 27, 04:02 PM ET
via exchange tick
T+1d
-1.48%
call -1.48% · α -1.47%
$92.44
settled 5mo ago
T+5d
-6.70%
call -6.70% · α -8.39%
$87.54
settled 5mo ago
T+20d
-7.63%
call -7.63% · α -13.10%
$86.67
settled 4mo ago
T+60d
+7.38%
call +7.38% · α +3.66%
$100.75
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Abbott Laboratories filed an 8-K reporting the adoption of amended and restated bylaws effective April 24, 2026 (Item 5.03) and provided standard form equity award agreements under the 2026 Incentive Stock Program (Exhibits 10.23 and 10.18). No material financial data, officer changes, or shareholder vote results were disclosed. The filing is routine and has no immediate trading implications.

Key Facts

  • Amended and restated bylaws adopted effective April 24, 2026.
  • Non-Qualified Stock Option Agreement and Performance Restricted Stock Unit Agreement forms filed as exhibits (placeholder terms).
  • No actual grant amounts, exercise prices, or performance targets disclosed.
  • Shareholder votes occurred (Item 5.07) but results not provided in filing.

Financial Impact

No financial impact estimable from filing; placeholder amounts for equity awards not specified.

Risk Factors

  • None from this filing; potential future dilution if equity grants are large, but amounts unknown.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
74% bullish (35 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-049434
Document: tm2612318d1_ex10-23.htm0001104659-26-049434
Document: tm2612318d1_ex10-18.htm0001104659-26-049434
22 reports for ABT
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+20▲ +17.16%Jul 1, 2026
Filters
Rows
Reports for ABT — sortable, filterable
TypeNow
Oct 2, 2026
today
ANALYST-UPGRADE
BULLISH ★ 4/10
$98.00 awaiting T+5awaiting T+5—$96.69 (−1.34%)
Sep 14, 2026
18d ago
Court Ruling
NEUTRAL ★ 1/10
$103.09 $102.98▼ −0.11%▼ −1.77%$96.69 (−6.21%)
Aug 11, 2026
7w ago
Court Ruling
NEUTRAL ★ 2/10
$109.72 $112.68▲ +2.70%▲ +3.10%$96.69 (−11.88%)
Aug 11, 2026
7w ago
Court Ruling
NEUTRAL ★ 1/10
$109.72 $112.68▲ +2.70%▲ +3.10%$96.69 (−11.88%)
Jul 31, 2026
9w ago
Institutional Cluster
MIXED ★ 4/10
$105.70 $107.81▲ +2.00%▼ −1.51%$96.69 (−8.52%)
Jul 31, 2026
9w ago
Court Ruling
NEUTRAL ★ 2/10
$105.70 $107.81▲ +2.00%▼ −1.51%$96.69 (−8.52%)
Jul 24, 2026
10w ago
Court Ruling
BULLISH ★ 5/10
$103.06 $105.61▲ +2.47%▲ +2.10%$96.69 (−6.18%)
Jul 16, 2026
11w ago
8-K
BULLISH ★ 6/10
$98.83 $100.75▲ +1.94%▲ +3.61%$96.69 (−2.17%)
Jul 14, 2026
11w ago
Court Ruling
NEUTRAL ★ 3/10
$88.96 $101.66▲ +14.28%▲ +15.57%$96.69 (+8.69%)
Jul 7, 2026
12w ago
Court Ruling
NEUTRAL ★ 1/10
$95.84 $88.96▼ −7.18%▼ −7.73%$96.69 (+0.89%)
Showing 10 of 22

US Market Status

Market Closed — Opens in 2m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access